Epix announces MS-325 deal, exchange offer

Epix Pharmaceuticals Inc. (NASDAQ:EPIX) sold U.S., Canadian and Australian rights to MS-325 (formerly Vasovist

Read the full 147 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE